July 12, 2014 — Dilon Technologies announced it obtained CE mark approval for its Navigator gamma probe system. The CE mark allows Dilon to begin marketing the device throughout the European Union. Dilon has expanded its distribution into the majority of European countries and has already received the first orders.
"The Navigator gamma probe has been strongly accepted by surgeons in the United States. Three major influences for surgeon acceptance has been the strong reliability, simple design and ease of operation," said Robert Moussa, Dilon president and CEO. "A comparable market response is anticipated for Europe and other countries around the world that recognize the CE mark."
The Navigator gamma system is used in radio-guided surgical procedures, primarily for lymphatic mapping and tumor localization. Over the last several decades, procedures such as sentinel lymph node mapping—first in melanoma, and more recently in breast—have become a gold standard of care among general surgeons and surgical oncologists. Additional applications for the Navigator gamma probes are in pulmonary wedge resection, parathyroid adenoma and laparoscopy.
For more information: www.dilon.com
October 30, 2026 
